Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023
"Human
Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis
to 2023".
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Summary
Human
immunodeficiency virus
(HIV) is a retrovirus that infects the cells of the immune system,
destroying or impairing their function. As the infection progresses,
the immune system becomes increasingly weaker, making the infected
person more susceptible to other infections. Since the first anti-HIV
drug, GlaxoSmithKlines (GSKs) Retrovir (azidothymidine), was approved
in 1987, major improvements have been made in the field of
antiretroviral therapy (ART). This rapid progress has been headlined
by the emergence of once-daily, single-tablet regimens (STRs) such as
Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir
disoproxil fumarate [TDF]), which offer patients an unparalleled
level of convenience.
Over
the forecast period, the major driver of growth in the US HIV
therapeutics market will be the launch of new drugs that offer
improvements in terms of the pill burden, tolerability, and efficacy.
Novel STRs will have the strongest positive impact on the market, and
the drugs within this class of ART regimens include ViiVs recently
launched INI-based STR, Triumeq, which was the first regimen to show
superiority over Atripla.
*This
is an on-demand report and will be delivered within 24 hrs.
(excluding weekends) of the purchase.
Scope
-
Overview of Human Immunodeficiency Virus (HIV) including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment
guidelines as well as an overview on the competitive landscape.
-
Detailed information on the key drugs in the US including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in the US from 2013-2023.
-
Analysis of the impact of key events as well the drivers and
restraints affecting the US Human Immunodeficiency Virus (HIV)
market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Human Immunodeficiency Virus (HIV).
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2013-2023 in the US
For
More Information Kindly Contact:
ResearchMoz
Global Pvt. Ltd.
90
State Street,
Albany,
NY 12207,
United
States
Blog
- http://bit.ly/2b1Ayn6
866-997-4948
(Us-Canada Toll Free),
+1-518-621-2074,
Email
to:
sales@researchmoz.us,
Comments
Post a Comment